Fujino T, Okamoto H, Nishiyama D, Hayata H, et al. Real-world data of polatuzumab vedotin with bendamustine and rituximab for Japanese relapsed and refractory DLBCL: a multicenter retrospective study. Leuk Lymphoma 2025;66:1425-1436.
PMID: 40134133